Navigation Links
Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Date:8/27/2008

SEATTLE, Aug. 27 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that executives will present a corporate update at the upcoming Morgan Stanley Global Healthcare Unplugged Conference to be held at the Grand Hyatt New York on Sept. 9, 2008. Dr. Peter Thompson, president, chief executive officer and chairman, and Dr. Scott C. Stromatt, newly appointed senior vice president and chief medical officer, are scheduled to present on Tuesday, Sept. 9 at 4:30 p.m. EDT. The presentation will be available via audio webcast on Trubion's investor website at investors.trubion.com.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

For more information, contact:

Trubion Pharmaceuticals Inc.

Jim DeNike

Senior Director, Corporate Communications

(206) 838-0500

jdenike@trubion.com

http://www.trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

(617) 576-5788

amyp@waggeneredstrom.com

TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Announces Presentations at April/May Investor Conferences
7. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... ... trial solutions, today announced safety software company AB Cube has joined its ... business segment to advance technology innovation across life sciences and healthcare. Under ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... by a wide range of overlapping clinical features. The advancement of targeted next-generation ... field of NDD research and testing. , However, designing a custom panel ...
(Date:7/17/2017)... ... July 17, 2017 , ... Co-Diagnostics, ... developed and intends both to manufacture and sell reagents used for diagnostic tests, ... Market. , Headquartered in Sandy, Utah, Co-Diagnostics’ intellectual property and technologies are protected ...
(Date:7/16/2017)... ... July 16, 2017 , ... ... instruments announced the launch of its new line of Rocking and Waving Shakers ... waving shaker models (both analog and digital) for laboratory applications in a variety ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
Breaking Biology News(10 mins):